Amparo Macías

558 total citations
15 papers, 437 citations indexed

About

Amparo Macías is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Amparo Macías has authored 15 papers receiving a total of 437 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Immunology and 6 papers in Oncology. Recurrent topics in Amparo Macías's work include Glycosylation and Glycoproteins Research (8 papers), Immunotherapy and Immune Responses (7 papers) and Cancer Research and Treatments (4 papers). Amparo Macías is often cited by papers focused on Glycosylation and Glycoproteins Research (8 papers), Immunotherapy and Immune Responses (7 papers) and Cancer Research and Treatments (4 papers). Amparo Macías collaborates with scholars based in Cuba, Argentina and Spain. Amparo Macías's co-authors include Rolando Pérez, Agustín Lage, Ana María Vázquez, Ana Hernández, Eduardo Suárez, Victor Gustavo Balera Brito, James W. Larrick, Daniel E. Gómez, Kirk E. Fry and Jorge Ernesto González Mesa and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Amparo Macías

14 papers receiving 422 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amparo Macías Cuba 7 231 216 184 176 52 15 437
Greene Mi United States 6 153 0.7× 256 1.2× 92 0.5× 212 1.2× 25 0.5× 14 389
Siri Juell Norway 12 148 0.6× 119 0.6× 166 0.9× 77 0.4× 30 0.6× 16 373
C R Zelnick United States 9 302 1.3× 285 1.3× 32 0.2× 128 0.7× 48 0.9× 9 447
Enrique Rengifo Cuba 11 371 1.6× 71 0.3× 252 1.4× 182 1.0× 20 0.4× 19 432
Kristin Mentz Germany 8 165 0.7× 283 1.3× 316 1.7× 158 0.9× 35 0.7× 10 507
Srimathi Srinivasan United States 9 208 0.9× 160 0.7× 93 0.5× 38 0.2× 20 0.4× 15 408
Roberto Sommavilla Switzerland 8 210 0.9× 184 0.9× 142 0.8× 238 1.4× 11 0.2× 16 452
Martijn Gerretsen Netherlands 9 172 0.7× 126 0.6× 75 0.4× 196 1.1× 35 0.7× 16 477
Julie A. Lofgren United States 9 198 0.9× 209 1.0× 58 0.3× 142 0.8× 16 0.3× 10 361
Peishan Lee Singapore 6 245 1.1× 111 0.5× 189 1.0× 38 0.2× 18 0.3× 12 351

Countries citing papers authored by Amparo Macías

Since Specialization
Citations

This map shows the geographic impact of Amparo Macías's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amparo Macías with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amparo Macías more than expected).

Fields of papers citing papers by Amparo Macías

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amparo Macías. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amparo Macías. The network helps show where Amparo Macías may publish in the future.

Co-authorship network of co-authors of Amparo Macías

This figure shows the co-authorship network connecting the top 25 collaborators of Amparo Macías. A scholar is included among the top collaborators of Amparo Macías based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amparo Macías. Amparo Macías is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Viada, Carmen, et al.. (2020). Evaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials. Bionatura. 5(1). 1056–1062. 1 indexed citations
2.
Macías, Amparo, et al.. (2016). P2.34: Vaxira and CIMAvax-EGF Therapeutic Vaccines Combination in the Advanced NSCLC Treatment. Journal of Thoracic Oncology. 11(10). S236–S237. 1 indexed citations
3.
Viada, Carmen, et al.. (2016). Security 1E10 anti-idiotypic vaccine in patients with tumors of different locations. Bionatura. 1(1). 13–19. 1 indexed citations
4.
Hernández, Maurenis, Ramon A. Ortiz, Elia Neninger, et al.. (2014). RANIDO: A phase III clinical trial of racotumomab-alum or nimotuzumab versus docetaxel in advanced non-small cell lung cancer patients.. Journal of Clinical Oncology. 32(15_suppl). TPS3111–TPS3111.
5.
Neninger, Elia, et al.. (2014). Safety and Efficacy of Racotumomab-Alum Vaccine as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer. International Journal of Clinical Medicine. 5(14). 844–850. 3 indexed citations
6.
Macías, Amparo, et al.. (2013). Seguridad del Racotumomab en el tratamiento de pacientes con cáncer de pulmón de células no pequeñas. SHILAP Revista de lepidopterología. 22(1). 10–14. 1 indexed citations
7.
Gómez, Daniel E., Ana Vázquez, Daniel F. Alonso, & Amparo Macías. (2013). Anti-idiotype antibodies in cancer treatment. Frontiers in Oncology. 3. 37–37. 4 indexed citations
8.
Gómez, Roberto, Elia Neninger, Ana María Vázquez, et al.. (2013). Active immunotherapy in patients with progressive disease (PD) after first-line therapy: Racotumomab experience.. Journal of Clinical Oncology. 31(15_suppl). 3086–3086. 3 indexed citations
9.
Hernández, Ana M Guerreiro, et al.. (2012). Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides – preclinical and clinical data. SHILAP Revista de lepidopterología. 2. 150–150. 31 indexed citations
10.
11.
Aguirre, Frank, et al.. (2011). Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer. International Journal of Breast Cancer. 2011. 1–6. 31 indexed citations
12.
Mulens‐Arias, Vladimir, Ana de la Torre, Patricia Marinello, et al.. (2010). Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients.. Human Vaccines. 6(9). 736–744. 36 indexed citations
13.
Hernández, Ana, Victor Gustavo Balera Brito, Amparo Macías, et al.. (2008). Characterization of the Antibody Response against NeuGcGM3 Ganglioside Elicited in Non-Small Cell Lung Cancer Patients Immunized with an Anti-Idiotype Antibody. The Journal of Immunology. 181(9). 6625–6634. 79 indexed citations
14.
Coloma, M J, et al.. (1990). Specific Amplification of Rearranged Immunoglobulin Variable Region Genes from Mouse Hybridoma Cells. Hybridoma. 9(5). 407–417. 34 indexed citations
15.
Pérez, Rolando, et al.. (1984). Epidermal growth factor receptors in human breast cancer. Breast Cancer Research and Treatment. 4(3). 189–193. 165 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Greene Mi Breakdown of academic impact, for papers by Siri Juell Breakdown of academic impact, for papers by C R Zelnick Breakdown of academic impact, for papers by Enrique Rengifo Breakdown of academic impact, for papers by Kristin Mentz Breakdown of academic impact, for papers by Srimathi Srinivasan Breakdown of academic impact, for papers by Roberto Sommavilla Breakdown of academic impact, for papers by Martijn Gerretsen Breakdown of academic impact, for papers by Julie A. Lofgren Breakdown of academic impact, for papers by Peishan Lee
Rankless by CCL
2026